<DOC>
	<DOCNO>NCT01144117</DOCNO>
	<brief_summary>In double-blind , placebo-controlled , parallel group trial , recombinant human erythropoietin ( rhEPO ) ( 48000 IU ) treatment placebo administer weekly i.v . 24 week : weekly 12 week bi-weekly 12 week . Methylprednisolone ( MP ) 1 g i.v . administer first second EPO/placebo administration . The 24-week treatment period follow 24-week observation period .</brief_summary>
	<brief_title>The Effects Erythropoietin Clinical Disability Brain Pathology Patients With Progressive Multiple Sclerosis</brief_title>
	<detailed_description>Patients primary progressive MS secondary progressive MS without relapse last 1 year suitable trial . In 56 patient enrol study . The primary outcome measure change baseline 24 week composite maximum gait distance , 9-hole peg test , TRAIL make B compare placebo-treatment group EPO-treatment group .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>age 19 60 year primary progressive MS secondary progressive MS without relapse last one year duration disease least 2 year Clinical disability progression observe 2 year prior screen per clinical judgment investigator . In addition , progression must document increase EDSS score least 0.5 point time 2 year prior Screening ; progression 1 point pyramidal , cerebellar , brain stem , visual sensory functional system last 2 year . Should document EDSS score available , write summary clinical evidence disability progression previous 2 year must submit ( example walk distance hand function ) . EDSS ( Expanded Disability Status Scale ) 4.06.5 MRI fulfil Barkhof criterion MS write informed consent pregnancy period breastfeed miss adequate contraceptive protection treatment steroid last 30 day treatment interferon , glatiramer acetate IVIG last1 month prior enrolment treatment azathioprin , mitoxantrone immunosuppressive 6 month prior enrolment cardiac insufficiency ( NYHA III/IV ) , cardiomyopathy , significant cardiac dysrhythmia require treatment , instable advanced ischemic heart disease ( CCS III IV ) , malignant hypertension ( systolic &gt; 180 , diastolic &gt; 110 ) history haematological disorder history renal insufficiency medical psychiatric circumstance impede restrict subject participation study manner intend contraindication contrast enhance MRI ( e.g . pace maker , aortic clip metal implant )</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Progressive Multiple Sclerosis</keyword>
</DOC>